Acuitas Therapeutics, Inc.’s Post

Managing a highly curated small molecule library isn’t just science, it’s an art — one that’s powered by automation, innovation, and attention to detail. 🎨🔬 At the XXVIII EFMC International Symposium on Medicinal Chemistry, Laura Mangiardi, Principal Research Scientist at IRBM, shared insights into our fully automated platform for compound collection management for High Throughput Screening. This platform addresses the growing complexity and size of compound libraries, which have expanded significantly with advancements in chemistry and medicinal design, underscoring the need for more efficient and scalable end-to-end management solutions in drug discovery. 💡Don’t miss this edition of “𝗗𝗶𝘀𝗰𝗼𝘃𝗲𝗿𝘆 𝗕𝗶𝘁𝗲𝘀” by IRBM, and mark your calendars for the upcoming SLAS (Society for Laboratory Automation and Screening) 2024 Sample Management Symposium to learn more about how we’re speeding up the discovery of new therapeutics by adding efficiency, accuracy, and scalability to every step of the process. #EFMC2024 #DrugDiscovery #MedicinalChemistry #IRBM

Thrilled to share our #RSCPoster: "Dual Stimuli-Responsive NanoSensoGel Formulation Technology to Prevent Chemotherapeutic-Induced Ototoxicity"! 🎉 This work explores the development of a dual stimuli-responsive NanoSensoGel, harnessing innovative chemistry for targeted inner ear drug delivery. 🔬 Through rational molecular design, we've engineered nanogel components that respond to ROS and temperature, enabling sustained and localized drug release. 🌡️ Our cell studies demonstrate efficient cellular uptake, triggered drug release, and remarkable ototoxicity protection. 🔥 This highlights the power of chemistry in driving design innovations, optimizing drug delivery, and preventing hearing loss induced by chemotherapy. 👂 Check out full publication in #JournalofControlledRelease (https://lnkd.in/dZgndqbj). The team: @Iulia Rus, Ethan Sparks, and Dr. Vibhuti Agrahari  Stay tuned for more exciting updates on this pioneering research! #RSCNano #NanoTechnology #OtologicalResearch #ChemistryMatters #drugdelivery #hearingloss #formulationdevelopment #designofexperiments #rscposter

Announcing the launch of CHI's 20th Annual Drug Discovery Chemistry: in San Diego April 2025! Check the website to view new as well as established, popular symposia and conference tracks. Consider submitting a proposal to speak. And of course SAVE THE DATE to attend! If you have speaker or topic suggestions, reach out to Tanuja Koppal and me. We look forward to programming, over the next two months, an exciting four days of the latest and greatest advancements in the design and discovery of small molecules (and some bigger molecules such as oral peptides) with therapeutic potential. #DrugDiscoveryChemistry #MedicinalChemistry

Did you know? TRC research chemicals are now fully available on the LGC Standards website. A better way to find the research chemicals needed for biopharma research along with all the reference materials you need for production. Everything at one site. View our entire solution for research, drug design and development, to drug manufacturing and qualification. Explore now at www.lgcstandards.com #ScienceForASaferWorld

Dr. Shaukat Ali in a recent interview with HS Talks-The Biomedical & Life Sciences Collections, sheds light on challenges and solutions of scaling up formulation and drug manufacturing. Please watch the video: https://lnkd.in/eG-Zam5U

✨ Excited to Share Our Latest Research Publication! ✨ I'm thrilled to announce that our research article, titled "Rebamipide Nanocrystal with Improved Physicomechanical Properties and its Assessment through Bio-mimicking 3D Intestinal Permeability Model," has been successfully published in Nanoscale, a journal with an impressive Impact Factor of 5.8! 🎉 This work is the result of months of hard work, perseverance, and collaboration, exploring innovative solutions to enhance drug delivery and absorption. By developing a Rebamipide Nanocrystal, we have significantly improved its physicomechanical properties, aiming to optimize oral drug delivery for better therapeutic outcomes. Moreover, using a bio-mimicking 3D intestinal permeability model, we were able to assess the nanocrystal's enhanced permeability, simulating real physiological conditions.💊🧬 This accomplishment would not have been possible without the unwavering guidance and support of my mentors, Dr. Santanu Kaity and Dr. Shubhadeep Roy. Your insights, encouragement, and belief in this project have been instrumental in its success.✨ A heartfelt thanks to the entire team for their dedication, and to Nanoscale for the opportunity to contribute to this esteemed journal 👏 This journal is Accessible at: https://lnkd.in/gexHX5xg #Research #Nanotechnology #PharmaceuticalScience #DrugDelivery #Nanoscale #Publication #Innovation #Gratitude

This paper demonstrates that COATSOME SS-OP, NOF's proprietary ionizable lipid for lipid nanoparticles (LNPs), is useful for oligonucleotide delivery. We are pleased to share this great result with you. #LNP, #LipidNanoparticles, #ionizablelipids, #delivery, #oligonucleotide, #siRNA, #ASO, #hepatic,

🌟 Join Us for an Exclusive Webinar! 🌟 Depixus is hosting a webinar on 9/10/24 (9am PT/ 12pm ET/ 6pm CET), entitled “See biology as it really happens – launch of a powerful magnetic force spectroscopy system to enable real-time study of the dynamics of individual molecular interactions at massive scale.” Depixus MAGNA One—the world’s first high-scale magnetic force spectroscopy platform—provides powerful new insights into how biomolecules interact. The technology opens the door to analyzing large numbers of individual interactions in parallel, revealing valuable details otherwise invisible to bulk measurement techniques. In this webinar, part of the MAGNA One commercial launch, Depixus’ CEO, Gordon Hamilton, will highlight this exciting new instrument system and its applications spanning fundamental research to drug discovery. In this webinar you’ll learn how their platform: 🧬Reveals biological variability in stunning detail by repeated analysis of thousands of individual interactions. 🔍 Gathers rich, detailed data from individual biomolecular interactions, revealing rare binding events often missed in bulk measurements. ⏱ Generates both kinetic & thermodynamic data. Don’t miss this chance to elevate your understanding of biomolecular interactions. Whether you’re involved in basic science, applied research, or drug development, the insights gained from Depixus MAGNA One could transform your work! Register here: https://lnkd.in/gzq-v2kx #RNATherapeutics #DrugDiscovery #Biotech #interactomics#Depixus

🧬 Unlocking the Potential of Small Molecules in Medicine 🧬 Why are small molecules a cornerstone in therapeutic development? Join Dr. Kishore V Renduchintala, Executive VP and Head of Discovery Sciences at LAXAI Life Sciences, at our Drug Discovery & Development Workshop as he unpacks the power and potential of small molecules to treat complex diseases. From design to synthesis, learn how advances in medicinal chemistry are leading to more effective and safer drug therapies. Kishore's session will cover: - Latest techniques in lead optimization - Challenges in drug design for targeted therapies - Case studies on breakthrough small molecule drugs 🌐 Dr. Renduchintala brings over two decades of experience and will share insights into how small molecules are designed, optimized, and developed into life-saving treatments. 📅 Event Date: 3-16 August, 2024 👉 Register Here: https://lnkd.in/ekGgYQkZ #MedicinalChemistry #DrugDesign #DDD2024

The PanOmics TargetID Framework – a modular system designed to assist clients in achieving their R&D goals – is an integral part of Evotec’s drug discovery program. PanOmics is the overarching term used to refer to the analysis of multiple data sets obtained from clinical studies and related biomedical sources. The TargetID Framework uses computational tools coupled with expert assessments to identify and rank potential drug targets based on their disease-relevance, druggability, biology, safety, competition, and efficacy. Being fully integrated into Evotec's drug discovery pipeline, it enables the client to leverage additional work packages and/or omics data, to aid the transition from target identification to IND. Download our whitepaper to find out more - https://hubs.ly/Q02dfwLB0 #researchneverstops